Burbank, CA, July 12, 2016 --(PR.com
)-- Imaging3™, Inc. (OTCBB: IGNG) announces today that it has successfully completed submission with FINRA and is now approved for trading under the ticker symbol IGNG.
Mr. Dane Medley, Chairman/CEO of Imaging3 - “Now that we have reemerged as a public company, we are evaluating new business endeavors, strategic acquisitions and other business transactions to enhance our value to customers and shareholders. We also hope to resubmit our 510(k) application to the Food and Drug Administration. This process will more than likely be managed by an outside consulting firms with specific expertise in navigating the FDA approval process.” Imaging3 will provide ongoing updates in the form of filings and press releases, all of which can be found on their website, www.imaging3.com,
under the news tab at the top of the page.
Imaging3, Inc., founded in 1993, has developed a medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time. Because these 3D images are instantly constructed in real-time, they can be used for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or in the human body. Visit the company’s website at http://www.imaging3.com
for more information
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, technological obsolescence, competition from other medical instrument(s) and imaging companies, lack of capital, unexpected costs, failure or delay of FDA approval, failure to obtain a trading symbol from FINRA or to satisfy the other requirements for reemerging as a public company, failure to consummate desired business combinations or transactions, delays or adverse rulings relating to its Chapter 11 bankruptcy action, absence of revenue, the impact on the national and local economies resulting from an economic recession or terrorist actions, and U.S. actions subsequently; unavailability of financing for the Company or its customers, product malfunction, potential product liability claims, and other factors detailed in reports filed by the Company. Imaging3 cannot assure that it will obtain regulatory approval for its products, successfully complete the Chapter 11 bankruptcy process, or obtain a trading symbol from FINRA.